Additive interactions between genetic susceptibility and physical activity account for nearly one third of excess T2D risk

Xuan Zhou[1], Germán D. Carrasquilla[1], Malene R. Christiansen[1], Roelof A.J. Smit[1,2], Lars Ängquist[1], Torben Hansen[1], Ruth J.F. Loos[1,2], Niels Grarup[1], Allan Linneberg[1,3,4], Tuomas O. Kilpeläinen[1], Jordi Merino[1,5]

Affiliations:

[1] Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark,

[2] Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

[3] Center for Clinical Research and Prevention, Copenhagen University Hospital - Bispebjerg and Frederiksberg, The Capital Region, Copenhagen, Denmark

[4] Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

[5] Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.

Words: 4,380 words

Corresponding authors' contact information:
Jordi Merino, Ph.D.
Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, 665 Blegdamsvej 3B, DK-2200 Copenhagen, Denmark,
Phone: +45 51 42 40 55
Email: jordi.merino@sund.ku.dk

Abstract

Regular physical activity is a well-established protective factor against type 2 diabetes (T2D), yet large variability exists in its metabolic benefits. Genetic factors could partially explain this variability, but studies examining gene-by-physical activity interactions in incident T2D are limited. Here, we used data from 10,627 participants from two population-based cohorts in the United States (*All of Us* Research Program) and Denmark (Inter99) to investigate how genetic risk and physical activity jointly influence T2D risk. Genetic risk was characterized using a polygenic score for T2D. Physical activity was measured using wearable devices in *All of Us* and self-reported questionnaires in Inter99. In *All of Us*, T2D incidence rates per 1,000 person-years were 2.1 (95% CI: 0.3, 3.9) for individuals with high physical activity and low genetic risk and 18.3 (95% CI: 13.4, 23.3) for those with low physical activity and high genetic risk (multivariable-adjusted hazard ratio of 6.9 (95% CI: 3.3, 14.4)). The interaction between physical activity and genetic risk deviated from additivity, with a relative excess risk due to interaction of 0.40 (95% CI: 0.11, 0.69; p = 0.003), accounting for 27% (95% CI: 5, 50) of excess T2D risk. These results were replicated in Inter99, where 44% (95% CI: 22, 67) of excess T2D risk was attributed to the interaction. These findings provide consistent evidence of interactions between genetic risk and physical activity on T2D risk, indicating that increasing physical activity among those with high genetic risk may represent an effective strategy for precision T2D prevention.

MAIN

The risk of developing type 2 diabetes (T2D) varies considerably among individuals, reflecting differences in susceptibility to the often collectively called environmental factors[1,2]. This variability underpins the significance of gene-environment interaction, wherein an individual's genetic profile, together with its downstream molecular effectors, interact with environmental exposures to uniquely modulate disease risk[3–6]. While gene-environment interactions are pervasive in nature, shaping phenotypes such as plant growth[7], bird migration[8], and grasshopper adaptation to new environments[9], identifying such interactions in the context of human diseases remains challenging[6]. This challenge is partly due to the limited precision and depth of environmental exposure assessments, in which recall bias are common[10,11], as well as the aetiological heterogeneity underlying diseases like T2D, where diverse pathophysiological pathways converge to the broad clinical features we use for diagnosis[12].

Physical activity is one of the most effective strategies for preventing T2D at both individual and population levels[13]. Yet, substantial variability in metabolic responses to exercise has been observed[14–18], which has critical implications for developing physical activity guidelines.[19] Family-based studies have demonstrated that exercise responsiveness exhibits a heritable component, with metabolic responses to exercise being more consistent within families than among unrelated individuals[16]. Data from the Diabetes Prevention Program (DPP) suggest that individuals with higher genetic risk may derive the greatest benefit from physical activity as part of an intensive lifestyle intervention[17]. Conversely, the Atherosclerosis Risk in Communities (ARIC) study found that the protective effects of physical activity were diminished in women with a higher genetic predisposition to insulin resistance[18]. These discrepancies, likely resulting from differences in study designs and populations, physical activity assessment methods, or

polygenic risk scores, without independent replication, underscore the need for more diverse and comprehensive research to develop evidence-based, precision-guided physical activity recommendations.

In this study, we tested the hypothesis that there is an interaction between genetic risk and physical activity, where the combined effect on T2D risk is greater than the sum of their individual effects. To test this hypothesis, we used data from two population-based cohorts in the United States and Denmark, encompassing 10,627 individuals without T2D at baseline. Furthermore, we decomposed genetic risk into distinct pathophysiological mechanisms underlying dysglycemia and examined potential interactions with physical activity.

RESULTS

Among the 15,523 participants from the *All of Us* cohort with linked Fitbit data at the time of our analysis, 4,654 participants had genetic information, clinical data with no diabetes at baseline, and valid follow-up physical activity data (Extended Data Fig.1). The median age of included participants was 52years (interquartile range (IQR) 36–62) and median body mass index (BMI) of 27.8 kg/m^2 (IQR 24.4–33.6) Approximately 75% were women, 91% were of European ancestry, and 75% had a college degree (Table 1). A total of 47.3 billion steps were recorded over a median follow-up period of 5.3 years (IQR 3.2–6.9), corresponding to 5,445,098 person-days of Fitbit monitoring. Daily step counts followed an approximately normally distribution (Extended Data Fig. 2), with a median of 7,858 steps per day (IQR 5,021–11,399). Compared to excluded participants, the study participants were more likely to be younger, female, of European ancestry, and have a lower BMI and education level (Supplementary Table 1).

The Inter99 cohort included 5,973 who had self-reported physical activity data, genetic data, and no diabetes at baseline (Extended Data Fig. 3). Participants in this cohort were of European ancestry, with a median age of 45 years (IQR 40–50), a median BMI of 25.6 kg/m^2 (IQR 23.1–28.5), and a nearly equal sex distribution (49% women; Table 1). The study sample was representative of the original Inter99 population (n=6,784), with minimal differences in clinical, demographic, or lifestyle characteristics (Supplementary Table 1).

In the *All of Us* cohort, 182 incident T2D cases were documented over 23,287 person-years of follow-up in. Crude T2D incidence rates per 1,000 person-year were 13.42 (95% CI: 10.86, 15.99) for participants in the highest tertile of the polygenic score and 3.99 (95% CI: 2.59, 5.40) for those in the lowest tertile (Table 2). The multivariable-hazard ratio (HR) for T2D risk

comparing participants with the highest tertile of the polygenic score to those with lowest tertile was 3.31 (95%CI: 2.30, 4.47; Table 2). When the polygenic score was modeled as a continuous variable, the adjusted HR per standard deviation (SD) increase in the polygenic score was 1.73 (95% CI: 1.47, 2.05).

In the Inter99 cohort, 371 incident T2D cases were documented over 103,916 person-years of follow-up. Crude T2D incidence rates per 1,000 person-year were 7.46 (95% CI: 6.54, 8.38) for participants in the highest tertile of the polygenic score and 0.85 (95% CI: 0.55, 1.16) for those in the lowest tertile (Table 2). The corresponding multivariable-adjusted HR for T2D risk was 7.12 (95%CI: 5.82, 8.70; Table 2). When the polygenic score was modeled as a continuous variable, the adjusted HR per SD increase in the polygenic score was 2.47 (95% CI: 2.25, 2.71).

Daily step counts were inversely associated with T2D risk. In the *All of Us* cohort, crude T2D incidence rates per 1,000 person-year were 11.43 (95% CI: 9.12, 13.74) for daily step counts at the lowest tertile and 4.82 (95% CI: 3.20, 6.44) for daily step counts at the highest tertile (Table 3). When physical activity was modeled continuously, each SD increase in daily step counts was associated with a lower risk of T2D, with an adjusted HR of 0.65 (95% CI: 0.53, 0.80). These findings replicated in the Inter99 cohort. Crude T2D incidence rates per 1,000 person-years were 5.70 (95% CI: 4.36, 7.05) for the lowest category of physical activity and 2.57 (95% CI: 1.67, 3.48) for the highest category (Table 3). Multivariable-adjusted analyses showed that reporting 7–12 hours of weekly physical activity had lower T2D risk compared to reporting 0–2 hours of weekly physical activity (HR=0.46, 95% CI: 0.30, 0.71).

Next, we investigated the joint associations of genetic risk and physical activity on T2D risk. Compared to *All of Us* individuals with low genetic risk and high physical activity levels, the

multivariable-adjusted HR for T2D was 2.00 (95% CI: 0.87, 4.73) for those with low genetic risk and low physical activity, 3.70 (95% CI: 1.73, 8.07) for those with intermediate genetic risk and low physical activity, and 6.90 (95% CI: 3.27, 14.40) for those with high genetic risk and low physical activity (Figure 1). T2D incidence rates per 1,000 person-years ranged from 2.1 (95% CI: 0.3, 3.93) for participants with low genetic risk and high physical activity levels to 18.3 (95% CI: 13.4, 23.3) for participants with high genetic risk and low physical activity levels (Figure 1). The joint associations of genetic risk and physical activity was higher than the sum of the risk associated with each factor alone, with a relative excess risk due to interaction (RERI) = 0.40 (95% CI: 0.11, 0.69; p=0.003). The proportion of contribution to excess T2D risk attributable to genetic susceptibility, physical activity, and their interaction was estimated at 40% (95% CI: 11, 70), 32% (95% CI: 19, 46), and 27% (95% CI: 5, 50), respectively (Table 4). No evidence of significant interactions on the multiplicative scale was observed between genetic risk and physical activity on the risk of T2D (p>0.05)

Similar patterns of interaction were observed in the Inter99 cohort. Compared to participants with low genetic risk and high physical activity levels, the multivariable-adjusted HR for T2D was 1.60 (95% CI: 0.70, 3.73) for those with low genetic risk and low physical activity, 4.10 (95% CI: 1.91, 8.60) for those with intermediate genetic risk and low physical activity, and 10.30 (95% CI: 4.93, 21.55) for those with high genetic risk and low physical activity (Figure 1). T2D incidence rates per 1,000 person-years ranged from 1.6 (95% CI: 0.4, 2.8) for participants with high physical activity levels and low genetic risk to 11.01 (95% CI: 7.8, 14.2) for participants with low physical activity levels and high genetic risk (Figure 1). Tests for additive interactions were significant, with RERI = 0.53 (95% CI: 0.30, 0.76; p = 0.007), and the proportion of excess T2D risk attributable to genetic susceptibility, physical activity, and their

interaction was estimated at 30% (95% CI: 9, 50), 26% (95% CI: 11, 41), and 44% (95% CI: 22, 67), respectively (Table 4).

We conducted a series of sensitivity analyses to further account for the influence of additional covariates such as BMI and family history of T2D. In models further adjusted for BMI, the association between genetic risk and T2D incidence remained virtually unchanged. However, the association between physical activity and T2D risk showed attenuation in both the *All of Us* and the Inter99 cohorts. As a result, the proportion of excess T2D risk attributed to the interaction reduced, with an estimate of 22% (95% CI: -12, 56) in the *All of Us* cohort and 38% (95% CI: -6, 83) in the Inter99 cohort (Supplementary Table 2). In models further adjusted for family history of T2D, the main findings persisted, indicating that the joint effects of genetic risk and physical activity were largely independent of familial predisposition (Supplementary Table 2).

In a secondary analysis, we generated pathway-specific polygenic scores to investigate whether the observed interactions were driven by specific diabetogenic processes. Based on genetic variants and weights from a previous study, we constructed eight-pathway specific polygenic scores representing distinct pathophysiological mechanisms underlying dysglycemia (Methods). Most of these polygenic scores were associated with an increased risk of T2D in both the *All of Us* and Inter99 cohorts, except for the residual glycemic polygenic score or the impaired liver/lipid metabolism polygenic score (Figure 2). We then investigated interactions between pathway-specific polygenic and physical activity. We showed evidence of additive interactions between physical activity and the lipodystrophy-related insulin resistance polygenic score that was consistent across the two studies. In *All of Us,* the relative excess risk due to the interaction between physical activity and the lipodystrophy polygenic score was 0.18 (95% CI: -0.03, 0.39; p=0.05; Figure 2) and the proportion of excess T2D risk attributed to the interaction was 21%

(95% CI: -3, 46; Supplementary Table 3). In *Inter99*, the relative excess risk due to interaction was 0.96 (95% CI: 0.07, 1.86; p=0.018; Figure 2), and the attributable type 2 diabetes risk proportion due to the interaction was estimated to be 48% (95% CI: 17, 80; Supplementary Table 3).

We further investigated whether these results were consistent across populations beyond those of European ancestry. Ancestry was ascertained based on genetic background and self-reported (Methods). Because there were only 2 incident cases among the 51 participants of South Asian group and 3 incident cases among the 93 East Asian group, the model did not converge. Among the African ancestry group (19 incident T2D cases among 260 participants), there was no evidence of associations between genetic susceptibility, physical activity, and T2D risk, nor of interactions between the two exposures (Supplementary Table 4).

Sex-stratified analyses were also conducted. In the *All of Us* cohort, interactions between genetic risk and physical activity were evident in both sexes. In men, the relative excess risk due to the interaction was 0.36 (95% CI: 0.06, 0.67; p=0.01) and the proportion of excess T2D risk attributed to the interaction was 39% (95% CI: -14, 62; Supplementary Table 5). In women, the relative excess risk due to the interaction was 0.42 (95% CI: -0.08, 0.92; p=0.05) and the proportion of excess T2D risk attributed to the interaction was 21% (95% CI: -2, 43; Supplementary Table 5). In the Inter99 cohort, these interactions were observed only in women, with a population attributable risk due to the interaction estimated at 58% (95% CI: 23, 93; Supplementary Table 5).

DISCUSION

Our findings from two independent population-based cohorts provide consistent evidence of a gradient in T2D risk driven by high genetic susceptibility and low physical activity levels. This gradient deviates from the additive contributions of these factors, with the confluence of high genetic risk and low physical activity accounting for approximately one-third of the excess T2D risk. Since additive interactions quantify differences in absolute risk reduction across populations[20], our results suggest that preventing the co-occurrence of these two risk factors could translate into preventing about one-third of T2D cases. This provides a compelling quantitative foundation for the development of more targeted T2D prevention strategies.

Our study builds on prior research investigating gene-environment interactions in T2D, emphasizing the preliminary synergistic effects of genetic susceptibility and physical activity[14,15,17,18]. For example, a UK Biobank study demonstrated an additive effect of accelerometer-based physical activity measures and polygenic risk scores on T2D risk, with greater absolute risk reductions observed among individuals at high genetic risk who engaged in moderate-to-vigorous physical activity[15]. Our results extend this body of evidence in three key ways. First, instead of relying on single time-point physical activity measurements, we utilized longitudinal data, focusing on physical activity prior to and leading up to a T2D diagnosis, with a median objectively measured physical activity monitoring period of 5.3 (IQR: 3.2, 6.9) years in the *All of US* cohort. Second, we validated our findings across geographically and demographically distinct cohorts using different physical activity assessment methods, demonstrating consistency and generalizability across studies. Third, we employed complementary polygenic scores denoting either overall genetic risk or specific diabetogenic processes. These scores were derived from an independent dataset that did not include the

participants from this study, thereby mitigating the risk of inflated type I error due to overlap between the discovery and the testing dataset. The use of these scores provides greater granularity in the molecular heterogeneity underlying T2D and helps identify diabetogenic processes more likely to interact with physical activity. These results underscore the relevance of gene-environment interactions in T2D and provide actionable insights to inform more target physical activity strategies.

T2D is a highly heterogeneous disease, characterized by multiple disrupted pathways converging into the common shared denominator of hyperglycemia.[12,21] While physical activity likely exerts broad protective effects across most pathways[22], our results suggest that pathways related to insulin resistance mediated through lipodystrophy may be particularly responsive to exercise. The lipodystrophy polygenic score used in this study comprises genetic variants associated with increased fasting insulin, waist-to-hip ratio, blood pressure, and triglycerides, as well as decreased body fat percentage, gluteofemoral adipose tissue volume, and HDL cholesterol. Functional studies indicate that these variants are enriched for regulatory elements in adipocytes, underscoring their biological relevance[12]. Previous research has shown that individuals with elevated T2D risk due to lipodystrophy-related insulin resistance mechanisms are also at increased risk for coronary artery disease[23], pointing towards the importance of this score to identify those at higher risk of T2D-related complications. While our findings suggest that promoting physical activity interventions among those at high T2D risk due to lipodystrophy-related insulin resistance processes could be especially beneficial, future studies should further investigate these interactions to inform more precise and effective prevention strategies.

Physical activity guidelines are central to public health recommendations for T2D prevention[13], with higher levels of physical activity consistently associated with reduced risk. However, current guidelines do not account for individual variability in physical activity responses, influenced by factors such as genetic background, body composition, and caloric intake. For instance, the ARIC study found that the antidiabetic effects of physical activity are attenuated in women with a higher genetic predisposition to insulin resistance[18], suggesting that greater physical activity may be needed to offset genetic risk. In another study from the *All of Us* Research Program, investigators showed that individuals with high genetic risk for obesity would need to walk an additional 2,300 steps daily to match the obesity risk of those with lower genetic risk[24]. Our models estimate that nearly a third of T2D cases would have been prevented if one of two exposures (increased genetic risk and low physical activity) were not present, supporting the integration of genetic and environmental factors into precision health strategies.

This study has several limitations. First, as an observational study, participants were not randomized to high- or low-physical activity groups, limiting causal inference interpretations. However, the consistency of findings across two independent cohorts strengthens their robustness. Our findings warrant recall-by-genotype studies specifically designed to test this hypothesis. Second, the relatively small number of incident T2D cases in the *All of Us* dataset, due to limited follow-up and a low proportion of participants with linked fitness tracking data, may have influenced our results. This is particularly relevant for the population attributable risk calculation, which is a population-specific calculation that is dependent on the prevalence of the exposure and its association with disease risk[25]. While estimated attributable risks are likely to change over time with changes in T2D rates, it was reasuring to see that the associations observed in *All of Us* were validated in a cohort with extended follow-up and double the number

of incident cases. Third, despite using comprehensive polygenic scores for overall T2D risk and specific pathophysiological mechanisms, genetic risks for related cardiometabolic diseases such as obesity may also contribute to T2D risk. We attempted to account for this by including family history of T2D or adjusting for BMI in secondary analyses, but confounding or bias could still exist. Future studies should confirm our findings. Finally, other molecular, clinical, or behavioral factors such as diet, body composition, or gut microbiome were not explicitly included in our analyses, potentially limiting the explanatory power of our models and influencing the population attributable risk calculation.

In conclusion, by quantifying the combined contributions of genetic risk and physical activity to T2D risk among 10,578 participants in two population-based cohorts, we found that their confluence accounts for approximately one-third of the excess T2D risk. These findings provide robust evidence that genetic risk and physical activity interact to influence T2D risk, highlighting the potential of targeted physical activity interventions, particularly in individuals with high genetic susceptibility, for precision T2D prevention.

METHODS

Study design and population

We used data collected from two prospective cohort studies including participants in the *All of Us* Research Program and the Inter99 study. Details on the design and execution of the *All of Us* and Inter99 have been published previously[26,27]. In the *All of Us*, we used Curated Data Repository (CDR) version 7 for Controlled Tier (C2022Q4R9). This dataset included information on physical measurements and vital signs collected at enrollment, surveys, electronic health record (EHR), Fitbit data, and genetic information from participants enrolled between May 6, 2018, and July 1, 2022. Our analyses focused on participants who owned a Fitbit and agreed to share their Fitbit, EHR, and genetic information. We excluded participants who did not wear a Fitbit for at least 6 months. Only the authorized authors who completed *All of Us* Research Program Responsible Conduct of Research Training accessed the deidentified data from the Researcher Workbench (a secured cloud-based platform). Since the authors were not directly involved with the participants, institutional review board review was exempted in compliance with *All of Us* Research Program policy.

Inter99 is a population-based pre-randomized lifestyle intervention study aiming to prevent ischemic heart disease and T2D. The study population comprised 61,301 individuals living in the western part of Copenhagen County. An age- and sex-stratified random sample of 13,016 individuals, with the majority of individuals at the age of 40 to 50 years, was drawn from the study population by the Civil Registration System using computer generated random numbers and pre-randomized into two groups. Baseline data were collected from March 1999 until January 2001 and there were 6,784 participants. Follow-up was conducted after one, three, five,

ten, and twenty years for a health examination, completion of questionnaires and risk assessment.

T2D polygenic scores

We generated a global polygenic score for T2D that captures overall genetic burden and eight pathway-specific polygenic scores denoting distinct pathophysiological processes using genetic variants and weights identified in a previous study[12].

In *All of Us* we followed standard procedures to filter genetic data to include only variants that had passed initial quality control[28]. For the global polygenic score, we used PRS–continuous shrinkage (PRScs)[29] to infer posterior SNP effect sizes under continuous shrinkage priors, with the scaling parameter auto-estimated [29]. Pathway-specific polygenic scores were generated by multiplying a variant's genotype dosage by its respective weight using PLINK, version 2.0. These scores were computed with ancestry-specific variants and weights. Polygenic scores were standardized within each ancestry to allow comparisons across scores computed in this study with different numbers of genetic variants (Extended Data Fig.4).

Individuals from Inter99 were genotyped using the Cardio-Metabochip and Human Exome BeadChip on an Illumina HiScan system (Illumina, San Diego, CA). Quality control and genotype calling have previously been described[30]. PRScs was used to produce the genome-wide scores with their quality-controlled SNP genotype data and these derived SNP weights. Pathway-specific polygenic scores were generated using PLINK. Polygenic scores were standardized (Extended Data Fig.4).

Physical activity assessment

Activity tracking data for this study came from the Bring Your Own Device program that allowed individuals who already owned a tracking device (Fitbit, Inc) to consent to link their activity data with other data in the *All of Us* cohort. By registering their personal device on the patient portal, participants could share all activity data collected since the creation of their personal device account. Activity data in *All of Us* are reported as daily step counts, and we used mean daily steps calculated on a monthly basis for each participant. Consistent with prior physical activity data curation approaches, days with less than 10 hours of wear time, less than 100 steps, or greater than 45 000 steps or for which the participant was younger than 18 years were removed[31]. In addition, we removed months with fewer than 15 valid days of monitoring.

Physical activity was self-reported in Inter99 and assessed with using validated questionnaires for work and leisure time activity[32] available at baseline, one-, three- and five-year follow-up. The level of physical activity was calculated by summing responses to the questions converted into minutes per week using a five-day working week.

Ascertainment of T2D

In *All of Us*, incident T2D were identified using any incident billing code in EHR. We excluded any new diagnoses coded during the first six months of monitoring, assuming that such conditions were likely prevalent, but not yet recognized clinically. The EHR data from different participating sites were mapped and harmonized using the Observational Medical Outcomes Partnership common data model[33].

In Inter99, we used data from separate nationwide health registries to define T2D events. In brief, we implemented a validated algorithm that calculates diabetes status and data of diagnosis based on a combination of registries[34] including the National Patient Register (diagnosis codes

[ICD-8: 249, 250; ICD-10: E10, E11]), the Medicines Products Register (purchase of any glucose lowering medication [ATC A10XXX]), the National Health Service Registry (use of podiatry treatment for people with diabetes), the Danish Adult Diabetes Database (diagnosis of diabetes), and the Eye Examination Database.

Statistical analysis

A flow diagram describes how many participants were excluded based on the criteria used to create the analytical dataset in *All of Us* cohort (Extended Fig 1) and Inter99 (Extended Fig 3). Descriptive statistics for participant's demographic and clinical characteristics were presented by median and IQR for continuous variables and frequency for categorical variables. Mann–Whitney *U* and chi-squared tests for continuous and categorical variables, respectively, were used to compare these clinical characteristics for the participants that were excluded versus included in the analytical dataset for this study.

We used Cox proportional hazard models to examine associations of genetic risk and physical activity with type 2 diabetes risk. For these analyses, we censored cases that occurred 6 months after completing enrolment to mitigate potential bias due to time-varying confounding. Person-time for each participant was calculated from the six month after completing baseline assessment to the diagnosis of T2D, death, loss to follow-up, or the end of the follow-up period, whichever came first. We modeled polygenic scores and physical activity as continuous variables. We also classified participants according to categories of genetic risk and physical activity (nine categories based on thirds of genetic risk and physical activity, with low genetic risk and high physical activity as reference) and conducted stratified analyses. We adjusted the multivariable

models for age (in years, continuous), sex (male, female) and genetic ancestry inferred from the first 10 principal components of genomic relationship matrix. We verified the proportional hazards assumption of the Cox model by using the Schoenfeld residuals technique (p values for the global test > 0.1). Analyses were conducted for complete cases given the small number of people with missing covariates. In secondary analyses,we further adjusted our models for BMI (quintiles of kg/m^2) and family history of diabetes (yes or no). The rationale for not including BMI and family history of diabetes in the main model was because these two exposures can act as a collider or a mediator[35].

We tested for additive and multiplicative interactions of genetic risk and physical activity with T2D incidence. For additive interactions we assessed the relative excess risk due to interaction (RERI), and further examined the decomposition of the joint effect—that is, the population attributable proportions to genetic risk alone, physical activity alone, and to their interaction[20]. For these analyses, we used the following formula (RERI = RR11 - RR10 - RR01 + 1) and (attributable proportion (AP) = RERI/ RR11)[20]. CIs for each of the interaction measures were calculated using the delta method described by Hosmer and Lemeshow. We tested for multiplicative interactions using the log-likelihood ratio test to compare the goodness of fit of a multivariable-adjusted model with and without the cross-product interaction term[36]. For these analyses, we considered genetic risk and physical activity as continuous variables and modeled the effect per 1SD, expect for physical activity in Inter99 that was defined as comparing high (7-12h/wk) to low physical activity (0-2h/wk).

We conducted analyses stratified by ethnic group in *All of Us* (European, African, East Asian, and South Asian) and sex-stratified analyses in both cohorts. Two-sided tests were used to assess whether polygenic risk for T2D and physical activity are associated with T2D incidence. A one-

sided test was used to assess whether RERI is greater than 0, i.e., testing the hypothesis that the combined effects of polygenic risk for T2D and physical activity exceeds their individual effects. All statistical analyses were performed using R software, version 4.0.3 (R Foundation). We followed the Better Precision-data Reporting of Evidence from Clinical Intervention Studies & Epidemiology (BePRECISE) reporting guideline[37].

REFERENCES

1. Franks, P. W. & McCarthy, M. I. Exposing the exposures responsible for type 2 diabetes and obesity. *Science* **354**, 69–73 (2016).

2. McCarthy, M. I. Painting a new picture of personalised medicine for diabetes. *Diabetologia* (2017) doi:10.1007/s00125-017-4210-x.

3. Franks, P. W., Pearson, E. & Florez, J. C. Gene-environment and gene-treatment interactions in type 2 diabetes: progress, pitfalls, and prospects. *Diabetes Care* **36**, 1413–21 (2013).

4. Franks, P. W. & Merino, J. Gene-lifestyle interplay in type 2 diabetes. *Curr Opin Genet Dev* **50**, 35–40 (2018).

5. DJ, H. Gene-environment interactions in human diseases. *Nat Rev Genet* **6**, (2005).

6. Herrera-Luis, E., Benke, K., Volk, H., Ladd-Acosta, C. & Wojcik, G. L. Gene–environment interactions in human health. *Nat Rev Genet* (2024) doi:10.1038/S41576-024-00731-Z.

7. Napier, J. D., Heckman, R. W. & Juenger, T. E. Gene-by-environment interactions in plants: Molecular mechanisms, environmental drivers, and adaptive plasticity. *Plant Cell* vol. 35 Preprint at https://doi.org/10.1093/plcell/koac322 (2023).

8. Bourret, A. & Garant, D. Candidate gene-environment interactions and their relationships with timing of breeding in a wild bird population. *Ecol Evol* **5**, (2015).

9. John, B. & Lewis, K. R. Chromosome variability and geographic distribution in insects. *Science (1979)* **152**, (1966).

10. Hebert, J. R. *et al.* Systematic errors in middle-aged women's estimates of energy intake: Comparing three self-report measures to total energy expenditure from doubly labeled water. *Ann Epidemiol* **12**, (2002).

11. Stockwell, T. *et al.* Under-reporting of alcohol consumption in household surveys: A comparison of quantity-frequency, graduated-frequency and recent recall. *Addiction* vol. 99 Preprint at https://doi.org/10.1111/j.1360-0443.2004.00815.x (2004).

12. Suzuki, K. *et al.* Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. *Nature* **627**, (2024).

13. 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2024. *Diabetes Care* **47**, (2024).

14. Osler, M. E. *et al.* Changes in gene expression in responders and nonresponders to a low-intensity walking intervention. *Diabetes Care* **38**, (2015).

15. Luo, M., Yu, C., Del Pozo Cruz, B., Chen, L. & Ding, D. Accelerometer-measured intensity-specific physical activity, genetic risk and incident type 2 diabetes: A prospective cohort study. *Br J Sports Med* **57**, (2023).

16. Hong, Y. *et al.* Familial resemblance for glucose and insulin metabolism indices derived from an intravenous glucose tolerance test in Blacks and Whites of the HERITAGE Family Study. *Clin Genet* **60**, (2001).

17. Raghavan, S. *et al.* Interaction of diabetes genetic risk and successful lifestyle modification in the Diabetes Prevention Programme. *Diabetes Obes Metab* **23**, 1030–1040 (2021).

18. Yann, C., Zhao, K., Amit Arora, C. & Hsu, C. H. Association of physical activity with lower type 2 diabetes incidence is weaker among individuals at high genetic risk. *Diabetologia* **57**, (2014).

19. Noone, J., Mucinski, J. M., DeLany, J. P., Sparks, L. M. & Goodpaster, B. H. Understanding the variation in exercise responses to guide personalized physical activity prescriptions. *Cell Metabolism* vol. 36 Preprint at https://doi.org/10.1016/j.cmet.2023.12.025 (2024).

20. VanderWeele, T. J. & Tchetgen Tchetgen, E. J. Attributing effects to interactions. *Epidemiology* **25**, 711–22 (2014).

21. Nair, A. T. N. *et al.* Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. *Nat Med* **28**, (2022).

22. Ashcroft, S. P., Stocks, B., Egan, B. & Zierath, J. R. Exercise induces tissue-specific adaptations to enhance cardiometabolic health. *Cell Metabolism* vol. 36 Preprint at https://doi.org/10.1016/j.cmet.2023.12.008 (2024).

23. Dicorpo, D. *et al.* Type 2 Diabetes Partitioned Polygenic Scores Associate With Disease Outcomes in 454,193 Individuals Across 13 Cohorts. *Diabetes Care* **45**, (2022).

24. Brittain, E. L. *et al.* Physical Activity and Incident Obesity Across the Spectrum of Genetic Risk for Obesity. *JAMA Netw Open* **7**, e243821–e243821 (2024).

25. Rockhill, B., Newman, B. & Weinberg, C. Use and misuse of population attributable fractions. *Am J Public Health* **88**, 15–19 (1998).

26. The "All of Us" Research Program. *New England Journal of Medicine* **381**, 668–676 (2019).

27. Jørgensen, T. *et al.* A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: Baseline results Inter99 (1). *Eur J Prev Cardiol* **10**, (2003).

28. All of Us Genomic Quality Report – User Support. https://support.researchallofus.org/hc/en-us/articles/27633757470228-All-of-Us-Genomic-Quality-Report.

29. Ge, T., Chen, C. Y., Ni, Y., Feng, Y. C. A. & Smoller, J. W. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nat Commun* **10**, (2019).

30. Borisevich, D. *et al.* Non-linear interaction between physical activity and polygenic risk score of body mass index in Danish and Russian populations. *PLoS One* **16**, (2021).

31. Master, H. *et al.* Association of step counts over time with the risk of chronic disease in the All of Us Research Program. *Nat Med* **28**, (2022).

32. Aadahl, M. & Jørgensen, T. Validation of a new self-report instrument for measuring physical activity. *Med Sci Sports Exerc* **35**, (2003).

33. Observational Medical Outcomes Partnership (OMOP) common data model (CDM) – User Support. https://support.researchallofus.org/hc/en-us/articles/360039685271-Observational-Medical-Outcomes-Partnership-OMOP-common-data-model-CDM.

34. Carstensen, B., Rønn, P. F. & Jørgensen, M. E. Prevalence, incidence and mortality of type 1 and type 2 diabetes in Denmark 1996-2016. *BMJ Open Diabetes Res Care* **8**, (2020).

35. Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. *Int J Epidemiol* **47**, 226–235 (2018).

36. Van Der Weele, T. J. & Knol, M. J. A tutorial on interaction. *Epidemiol Methods* **3**, (2014).

37. Lim, S. S. *et al.* Reporting guidelines for precision medicine research of clinical relevance: the BePRECISE checklist. *Nature Medicine 2024 30:7* **30**, 1874–1881 (2024).

Acknowledgements:

We gratefully acknowledge *All of Us* and Inter99 participants for their contributions, without whom this research would not have been possible. The *All of Us* Research Program is supported by grants 1 OT2 OD026549, 1 OT2 OD026554, 1 OT2 OD026557, 1 OT2 OD026556, 1 OT2 OD026550, 1 OT2 OD 026552, 1 OT2 OD026553, 1 OT2 OD026548, 1 OT2 OD026551, 1 OT2 OD026555, IAA AOD21037, AOD22003, AOD16037, and AOD21041 (regional medical centers); grant HHSN 263201600085U (federally qualified health centers); grant U2C OD023196 (data and research center); 1 U24 OD023121 (Biobank); U24 OD023176 (participant center); U24 OD023163 (participant technology systems center); grants 3 OT2 OD023205 and 3 OT2 OD023206 (communications and engagement); and grants 1 OT2 OD025277, 3 OT2 OD025315, 1 OT2 OD025337, and 1 OT2 OD025276 (community partners) from the National Institutes of Health (NIH).

This study was also supported by the Novo Nordisk Foundation grant NNF23SA0084103 and the European Union. JM was additionally supported by grants from the European Commission (HORIZON-EIC-2023-PATHFINDERCHALLENGES-01 - 101161509) and the EFSD/NNF Future Leaders Award (#0094134). RL was additionally supported by personal grants from the Novo Nordisk Foundation (Laureate award no. NNF20OC0059313) and the Danish National Research Fund (Chair DNRF161). TOK and MRC and were additionally supported by grants from the Novo Nordisk Foundation (NNF22OC0074128) and EFSD/Lilly European Diabetes Research Programme.

Ethics declarations:

Competing interest: The authors declare no competing interests.

Role of the Funder/Sponsor:

The funders had no role in the design and conduct of the study; collection, management, and interpretation; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.

Contributors statement:

XJ and JM take responsibility for the integrity and accuracy of the work. XZ, GDC, TOK, and JM designed the research. TOK and JM obtained funding for the proposed research. XZ and LA conducted the statistical analysis. All authors contributed to the critical revision of the manuscript for important intellectual content. All authors approved the final version of the manuscript. The corresponding authors attest that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Data Accessibility:

To ensure privacy of participants, data used for this study are available to approved researchers following registration, completion of ethics training and attestation of a data use agreement

through the All of Us Research Workbench platform, which can be accessed via https://workbench.researchallofus.org/login. Code used for this study can be made available to users of the *All of Us* Research Workbench platform by contacting our study team.

Data from Inter99 are available upon request and approval.

Copyright/license for publication:

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide license to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) license any third party to do any or all of the above.

Table 1. Baseline characteristics of the included participants.

	All of Us (n=4,654)	**Inter99 (n=5,973)**
Person-y[ϕ]	23,287	103,916
Age, years	52 (36-62)	45 (40-50)
Sex, Women, No. (%)	3,469 (75)	2,930 (49)
BMI, kg/m^2	27.8 (24.4-32.5)	25.6 (23.1-28.5)
Family history of diabetes, No. (%)	1,356 (29)	-
Smoker, No. (%)	1,460 (31)	2,083 (35)
Self-reported race/ethnicity[ε]		
White, No. (%)	4,250 (91)	5,973 (100)
African, No. (%)	260 (6)	-
East Asian, No. (%)	93 (2)	-
South Asian, No. (%)	51 (1)	-
Education		
College degree, No. (%)	3,387 (75)	1,769 (37)
Some/No college, No. (%)	1,137 (25)	2,998 (63)

Table Legend: Values are medians (interquartile range) for continuous variables; numbers and (percentages) for categorical variables.

Table 2: Adjusted hazard ratios of T2D risk according to genetic risk categories.

	Low genetic risk	Intermediate genetic risk	High genetic risk	P for trend
***All of Us* (n=4,654)**				
No. of events/person-years	31 / 7,765	50 / 7,699	105 / 7,823	—
Incidence rate (1,000 person-years; 95% CI)	4.0 (2.6-5.4)	6.5 (4.7-8.3)	13.4 (10.9-16.0)	—
Multivariable-adjusted model	1.00 (Ref)	1.82 (1.52-2.19)	3.31 (2.30-4.74)	<0.001
Inter99 (n=5,973)				
No. of events/person-years	30 / 35,250	89 / 34,873	252 / 33,793	—
Incidence rate (1,000 person-years; 95% CI)	0.9 (0.6-1.2)	2.6 (2.0-3.1)	7.5 (6.5-8.4)	—
Multivariable-adjusted model	1.00 (Ref)	2.65 (2.40-2.93)	7.12 (5.82-8.70)	<0.001

Table Legend: Hazards ratios and 95% CI for T2D risk. Genetic risk was categorized in three categories based on polygenic score distribution. Cox proportional hazards models were adjusted for age (in years, continuous), sex (male, female), and the first 10 principal components of the genomic relationship matrix.

Table 3: Adjusted hazard ratios of T2D risk according to physical activity levels.

	***All of Us* (n=4,654)**				**Inter99 (n=5,973)**				
	Low PA	**Intermediate PA**	**High PA**	**P for trend**	**0-2h/wk**	**2-4h/wk**	**4-7h/wk**	**7-12h/wk**	**P for trend**
No. of events/person-years	34 / 7,055	58 / 8,009	94 / 8,222	—	31 / 12,051	195 / 56,084	76 / 23,675	69 / 12,104	—
Incidence rate, 1,000 person-years; 95% CI)	4.8 (3.2-6.4)	7.2 (5.4-9.1)	11.4 (9.1-13.7)	—	2.6 (1.7-3.5)	3.5 (3.0-4.0)	3.2 (2.5-3.9)	5.7 (4.4-7.01)	—
Multivariable model	1.00 (Ref)	0.68 (0.57-0.82)	0.40 (0.26-0.62)	<0.001	1.00 (Ref)	0.55 (0.40-0.77)	0.55 (0.42-0.74)	0.46 (0.30-0.71)	<0.001

Table Legend: Hazards ratios and 95% CI for T2D risk. Cox proportional hazards models were adjusted for age (in years, continuous), sex (male, female), and the first 10 principal components of the genomic relationship matrix.

Table 4 Additive interactions between physical activity and global polygenic risk of T2D.

	All of Us	**Inter99**
Main effects		
Physical activity†	1.47 (1.15, 1.80)	1.90 (0.93, 2.86)
Polygenic score‡	1.59 (0.95, 2.23)	2.02 (1.32, 2.73)
Joint effect	2.47 (1.63, 3.30)	4.45 (2.30, 6.61)
Relative excess risk due to interaction		
Relative excess risk due to interaction	0.40 (0.11, 0.69)	1.53 (0.30, 2.76)
P value	0.003	0.007
Attributable risk proportion, %		
Daily step count	32.4 (18.7, 46.1)	26.0 (10.9, 41.1)
Polygenic score	40.3 (10.9, 69.7)	29.7 (9.3, 50.0)
Additive interaction	27.3 (5.1, 49.5)	44.4 (22.1, 66.6)

Table Legend: Multivariable adjusted risk of type 2 diabetes estimated from Cox proportional hazards models adjusted for age, sex, and the first ten principal components of genomic relationship matrix. The joint analysis was conducted to quantitatively estimate the combined association of physical activity and genetic risk simultaneously with the incidence of type 2 diabetes. For *All of Us*, relative excess risk due to interaction (RERI) is based on joint effects of a one-standard-deviation increase in PRS and a one-standard-deviation decrease in daily step count using the following formula (RERI = RR11 - RR10 - RR01 + 1). The model's attributable risk proportion due to the interaction was calculated as AP = RERI/ RR11[20]. For Inter99, RERI is based on joint effects of a one standard-deviation increase in the polygenic score and a reduction in weekly physical activity from 7-12h to 0-2h.

† per SD increase in daily step counts.

‡ per SD increase in the global polygenic scores.

Figure 1. Risk of incident type 2 diabetes by global polygenic risk score for type 2 diabetes, physical activity and study cohort.



Figure Legend: Risk is indexed using crude incidence rate and hazard ratio adjusted for age, sex and genetic ancestry. *HR* hazard ratio. Panel A. Dots correspond to averages of daily step count tertiles, which are ~ 5k, ~ 8k and ~13k. Histograms along the y-axis (to the right) show the density of daily step counts. Incidence rates are computed for tertiles of daily step counts. Panel B. Bar plots along the y axis (to the right) are for bins of weekly physical activity. Incidence rates are computed for all bins.

Figure 2. Pathway-specific polygenic risk for T2D and its interaction with physical activity on the incidence of T2D.



Figure Legend: Panel A shows adjusted HRs and 95% CI for type 2 diabetes risk per 1-SD increase in pathway-specific polygenic scores. PI: proinsulin. P values are based on a two-sided test of the hypothesis that HR differs from one. Panel B displays RERI and 95% CI, assessing additive interaction between polygenic scores and physical activity. For All of Us, RERI is based on the joint effects of a 1-SD increase in polygenic scores and a 1-SD decrease in daily step count. For Inter99, RERI is based on joint effects of a 1-SD increase in polygenic scores and a reduction in weekly physical activity from 7-12h to 0-2h. P values for RERI are based on a one-sided test of the hypothesis that the combined effect of polygenic risk and physical activity is greater than the sum of the two individual factors (RERI > 0).